<SEC-DOCUMENT>0001558370-22-010476.txt : 20220630
<SEC-HEADER>0001558370-22-010476.hdr.sgml : 20220630
<ACCEPTANCE-DATETIME>20220630143216
ACCESSION NUMBER:		0001558370-22-010476
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220630
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		221057598

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>tmb-20220630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 6/30/2022 06:21:31 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Washington,&#160;D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">FORM&#160;6-K</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOR THE&#160;MONTH OF JUNE 2022</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;white-space:pre-wrap;">COMMISSION FILE NUMBER 001-38976  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;">Genmab A/S</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:18pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Exact name of Registrant as specified in its charter)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Kalvebod Brygge 43</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">1560 Copenhagen V</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Denmark</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">+45 70 20 27 28</b><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;"><br></b><font style="color:#333333;font-family:'Arial','Helvetica','sans-serif';font-size:9.5pt;background:#ffffff;">(Address of principal executive offices)</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0 auto;" align="center"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Form&#160;20-F&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      Form&#160;40-F&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(1)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Indicate by check mark if the registrant is submitting the Form&#160;6-K in paper as permitted by Regulation&#160;S-T Rule&#160;101(b)(7)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Yes&#160;</font><font style="font-family:'Times New Roman';font-size:10pt;">&#9723;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">      No&#160;</font><font style="font-family:'Times New Roman';">&#8999;</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;white-space:pre-wrap;">  </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="background:#ffffff;">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font>incorporated by reference<font style="background:#ffffff;">&#160;in Genmab A/S&#8217;s registration statements on&#160;</font><font style="background:#ffffff;">Form&#160;S-8</font><font style="background:#ffffff;">&#160;(File&#160;No.&#160;333-232693)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">SIGNATURE</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">nthony</p></div></div></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">GENMAB A/S</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">BY:</font></p></td><td style="vertical-align:bottom;width:45.3%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">/s/ Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;border-top:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name: Anthony Pagano</font></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title: Executive Vice President &amp; Chief Financial Officer</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">DATE: June 30, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">EXHIBIT&#160;INDEX</b></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.1116867%;width:102.22%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:13.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">O</font></p></div></div></td><td style="vertical-align:top;width:86.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:13.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u></p></td><td style="vertical-align:top;width:86.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Description of Exhibit</u></p></td></tr><tr><td style="vertical-align:top;width:13.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:86.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:13.54%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">99.1</p></td><td style="vertical-align:top;width:86.45%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;">Company Announcement Dated June 30, 2022: Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody&#174;-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tmb-20220630xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 6/30/2022 06:21:44 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20220630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody&#174;-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:12pt;font-weight:bold;">Company Announcement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">COPENHAGEN, Denmark; June 30, 2022</b><a name="_Hlk71018734"></a><a name="_Hlk105147788"></a><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> &#8211; Genmab A/S (Nasdaq: GMAB) </b><font style="font-family:'Arial','Helvetica','sans-serif';">today announced its intent to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody&#174;-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), in the second half of 2022. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The BLA submission is supported by results from the large b-cell lymphoma (LBCL) cohort of the pivotal EPCORE&#8482; NHL-1 open-label, multi-center trial evaluating the safety and preliminary efficacy of epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-cell non-Hodgkin lymphoma (B-NHL). In April 2022, Genmab and AbbVie announced the topline results from EPCORE&#8482; NHL-1 trial. In June 2022, primary results were presented in a late-breaking oral presentation as part of the Presidential Symposium at the 27</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">th&#160;</sup><font style="font-family:'Arial','Helvetica','sans-serif';">Annual Meeting of the European Hematology Association (EHA2022) in Vienna, Austria. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;Relapsed or refractory large B-cell lymphoma is often difficult to treat, and patients are in need of novel therapies that are effective, tolerable and accessible,&#8221; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. &#8220;The results from the EPCORE NHL-1 trial, and other clinical trials evaluating epcoritamab in a variety of patients and treatment settings, have demonstrated that epcoritamab has the potential to offer people living with LBCL a new therapeutic advance with a manageable safety profile.&#8221;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Epcoritamab is being co-developed by Genmab and AbbVie as part of the companies&#39; oncology collaboration. The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies, including an ongoing phase 3, open-label, randomized trial evaluating epcoritamab as a monotherapy in patients with relapsed/refractory DLBCL (NCT: 04628494). </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Large B-cell Lymphoma (LBCL)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">LBCL is a fast-growing type of non-Hodgkin&#8217;s lymphoma (NHL), a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. There are an estimated 150,000 new LBCL cases each year globally. LBCL includes DLBCL, which is the most common type of NHL worldwide and accounts for approximately 31 percent of all NHL cases.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-2">i</a></sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">,</sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-3">ii</a></sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">,</sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-4">iii</a></sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">,</sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-5">iv</a></sup><font style="font-family:'Arial','Helvetica','sans-serif';"> </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About the EPCORE&#8482; NHL-1 Trial</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><a name="_Hlk106032843"></a><font style="font-family:'Arial','Helvetica','sans-serif';">EPCORE&#8482; NHL-1 is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab </font><font style="font-family:'Arial','Helvetica','sans-serif';">including a phase 1 first-in-human, dose escalation part; a phase 2 expansion part; and an optimization part. The trial was designed to evaluate subcutaneous epcoritamab in patients with relapsed, progressive or refractory CD20+ mature B-NHL, including LBCL and DLBCL. Data from the dose escalation part of the study, which determined the recommended phase 2 dose, were published in&#160;</font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">The Lancet</i><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;in 2021. In the phase 2 expansion part, additional patients are treated with epcoritamab to further explore the safety and efficacy of epcoritamab in patients with different types of relapsed/refractory B-NHLs who had limited therapeutic options.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">The primary endpoint of the phase 2 expansion part was overall response rate (ORR) as assessed by an IRC. Secondary efficacy endpoints included duration of response, complete response rate, progression-free survival, overall survival, time to response, time to next therapy, and rate of minimal residual disease negativity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 26</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 1/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><img src="tmb-20220630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:44.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:151.48pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:13pt;font-weight:bold;">Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody&#174;-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Epcoritamab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Epcoritamab is an investigational IgG1-bispecific antibody created using Genmab&#39;s proprietary DuoBody technology. Genmab&#39;s DuoBody-CD3 technology is designed to direct cytotoxic T cells selectively to elicit an immune response towards target cell types. Epcoritamab is designed to simultaneously bind to CD3 on T cells and CD20 on B-cells and induces T cell mediated killing of CD20+ cells.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-6">v</a></sup><font style="font-family:'Arial','Helvetica','sans-serif';"> CD20 is expressed on B-cells and a clinically validated therapeutic target in many B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma and chronic lymphocytic leukemia.</font><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-7">vi</a></sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;">,</sup><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:7.5pt;vertical-align:top;"><a style="vertical-align:super;" href="#endnote-8">vii</a></sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">About Genmab </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab&#8217;s vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people&#8217;s lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab&#8217;s proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Genmab&#160;is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan. For more information, please visit Genmab.com and follow us on Twitter.com/Genmab.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Genmab Media Contact:</b><font style="display:inline-block;width:29.54pt;"></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"><br></b><font style="font-family:'Arial','Helvetica','sans-serif';">Marisol Peron, Senior Vice President, Communications and Corporate Affairs</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">T: +1 609 524 0065; E:&#160;mmp@genmab.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Genmab Investor Relations: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Andrew Carlsen, Vice President, Head of Investor Relations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">T: +45 3377 9558; E: acn@genmab.com </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><font style="font-size:10pt;"><a name="_Hlk34743654"></a></font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Genmab Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">This Media Release contains forward looking statements. The words &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;anticipate&#8221;, &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on www.genmab.com</i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;"> and the risk factors included in Genmab&#8217;s </i><font style="font-size:10pt;"><a name="_Hlk35592020"></a></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">most recent Annual Report on Form 20-F </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">and other filings </i><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br></font><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; Genmab in combination with the Y-shaped Genmab logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;HuMax</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;DuoBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;DuoBody&#160;in combination with the&#160;DuoBody&#160;logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;HexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;HexaBody&#160;in combination with&#160;the&#160;HexaBody&#160;logo</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;DuoHexaBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">;&#160;HexElect</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">; and&#160;UniBody</i><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:6pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">. </i></p><div style="margin-bottom:5pt;margin-top:15pt;width:25%;border-bottom:1px solid black;"></div><a name="endnote-2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">i</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> &quot;Diffuse Large B-Cell Lymphoma.&quot; Lymphoma Research Foundation, </font>https://www.lymphoma.org/aboutlymphoma/nhl/dlbcl/<font style="font-family:'Arial','Helvetica','sans-serif';">. Date accessed: 7 June 2022.</font></p><a name="endnote-3"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">ii</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> &quot;Non-Hodgkin Lymphoma.&quot; Lymphoma Research Foundation, https://lymphoma.org/aboutlymphoma/nhl/. Date accessed: 7 June 2022.</font></p><a name="endnote-4"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">iii</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Sehn, Salles. &quot;Diffuse Large B-Cell Lymphoma.&quot; </font><font style="font-family:'Arial','Helvetica','sans-serif';">N Engl J Med. 2021;384:842-858. DOI: 10.1056/NEJMra2027612</font></p><a name="endnote-5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">iv</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Martelli, Ferreri, Agostinelli, et al. &quot;Diffuse large B-cell lymphoma.&quot; Crit Rev Oncol Hematol. 2013;87(2):146-71. DOI: 10.1016/j.critrevonc.2012.12.009</font></p><a name="endnote-6"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">v</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Engelberts et al. &quot;DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.&quot; EBioMedicine. 2020;52:102625. DOI: 10.1016/j.ebiom.2019.102625</font></p><a name="endnote-7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">vi</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Rafiq, Butchar, Cheney, et al. </font><font style="font-family:'Arial','Helvetica','sans-serif';">&quot;Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties.&quot; J. Immunol. 2013;190(6):2702-2711. DOI: 10.4049/jimmunol.1202588 </font></p><a name="endnote-8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><sup style="font-family:'Arial','Helvetica','sans-serif';font-size:5.25pt;vertical-align:top;">vii</sup><font style="font-family:'Arial','Helvetica','sans-serif';"> Singh, Gupta, Almasan. &quot;Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response.&quot; J Cancer Sci Ther. 2015;7(11):347-358. DOI: 10.4172/1948-5956.1000373</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:12pt 0pt 0pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:fixed;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Genmab A/S</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Tel: +45 7020 2728</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Company Announcement no. 26</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Kalvebod Brygge 43</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">Fax: +45 7020 2729</p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">Page 2/2</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">21560 Copenhagen V, Denmark</p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;">www.genmab.com </p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">CVR no. 2102 3884</p></td></tr><tr><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:34%;margin:0pt;padding:0pt;"><p style="font-family:'Arial','Helvetica','sans-serif';font-size:8pt;text-align:right;margin:0pt;">LEI Code 529900MTJPDPE4MHJ122</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tmb-20220630xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tmb-20220630xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
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M;')RHZ9S\[_L\ZYXCL?C+X7CT*[NS<7=]''<PK(S)- 3F7S!T(";CD]" >M
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4I5JU,PQ5N:I9)+5**\W:[?4__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
